Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA-HCM trial of rivaroxaban for thromboembolic prevention in hypertrophic cardiomyopathy with impaired left atrial strain
2024-511084-28-00Phase 4Authorised
- Sponsor
- CHU Rennes
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by CHU Rennes. Primary endpoint: Composite of all-cause death, myocardial infarction, stroke, silent brain infarction, and systemic embolism. Planned start Jan 2026; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2024-511084-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511084-28-00.